Ma Tianyi, Huang Yuli, Li Wensheng, Zhong Jianghua, Yang Hui, Zhou Yilei, Li Meijun, Zhong Wenhao, Cao Yue, Lu Shijuan, Hu Yunzhao
Department of Cardiology, Shunde Hospital, Southern Medical University, Foshan, China.
Department of Cardiology, Affiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou, China.
Cardiol Res Pract. 2021 Mar 25;2021:6673313. doi: 10.1155/2021/6673313. eCollection 2021.
At present, COVID-19 is sweeping the world, and all countries are actively responding. During the COVID-19 epidemic, the treatment of patients with acute myocardial infarction (AMI) may be affected.
We reviewed data of patients with AMI from January 23 to April 23, 2020 (2020), and January 23 to April 23, 2019 (2019), who were admitted to two hospitals from Southern China. We collected clinical characteristics, comorbidities, treatment, prognosis, and key time segments to analyze.
The total number of patients that had been diagnosed with AMI in the two hospitals was 218 in 2020 and 260 in 2019. The number of AMI patients that were admitted to hospitals per day decreased in 2020. The percentage of patients with AMI who refused hospitalization in 2020 was significantly higher than that in 2019 (5.0% vs 1.5%, =0.028). There is no statistical difference in symptoms of the first medical contact (S2FMC) time between 2020 and 2019 (=0.552). Door-to-balloon (D2B) time of ST-elevation myocardial infarction (STEMI) patients who were treated with a primary percutaneous coronary intervention (pPCI) in 2020 was 79 (63.75-105.25) mins, while D2B time in 2019 was 57.5 (41.5-76.5) mins, which was statistically different from the two groups.
COVID-19 had an impact on the number of AMI patients who were admitted to hospitals and the time of treatment. During the COVID-19 epidemic, the number of AMI patients that were admitted to hospitals per day was decreased, while the percentage of AMI patients that refused therapy in these two hospitals increased, and the D2B time of STEMI patients was also delayed.
目前，新型冠状病毒肺炎（COVID-19）正在全球蔓延，各国都在积极应对。在COVID-19疫情期间，急性心肌梗死（AMI）患者的治疗可能会受到影响。
我们回顾了2020年1月23日至4月23日以及2019年1月23日至4月23日期间收治于中国南方两家医院的AMI患者的数据。我们收集了临床特征、合并症、治疗情况、预后以及关键时间节点进行分析。
两家医院2020年确诊AMI的患者总数为218例，2019年为260例。2020年每日入院的AMI患者数量有所减少。2020年拒绝住院的AMI患者比例显著高于2019年（5.0%对1.5%，P = 0.028）。2020年与2019年首次医疗接触症状（S2FMC）时间无统计学差异（P = 0.552）。2020年接受直接经皮冠状动脉介入治疗（pPCI）的ST段抬高型心肌梗死（STEMI）患者的门球时间（D2B）为79（63.75 - 105.25）分钟，而2019年为57.5（41.5 - 76.5）分钟，两组之间存在统计学差异。
COVID-19对AMI患者的入院数量及治疗时间产生了影响。在COVID-19疫情期间，每日入院的AMI患者数量减少，而这两家医院中拒绝治疗的AMI患者比例增加，STEMI患者的D2B时间也有所延迟。
